Keeping Track: A Lilly Breast Cancer Approval, A Couple Of CRLs, And A Plethora Of Priority Reviews

The latest drug development news and highlights from our Performance Tracker.

Keeping Track Feature image

The US FDA showed off its speed last week with its review of Eli Lilly & Co.'s breast cancer treatment Verzenio (abemaciclib), approving the cyclin dependent kinase 4/6 (CDK4/6) inhibitor in 4.76 months. It marks the agency's fastest approval so far of 2017.

A few companies, conversely, faced setbacks. Intarcia Therapeutics Inc. was hit with a complete response letter (CRL) for its...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet